MTX-439

Phase 1Biologic

MMediar Therapeutics

MTX-439 is one of 6 biologic programs targeting Diabetic Kidney Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetic Kidney DiseaseRecruiting

Diabetic Kidney DiseasePhase 1

Recruiting

Competition

Competitive Landscape

7 competitors in Diabetic Kidney Disease

#DrugCompanyPhaseTrials

Kerendia

Bayer

Approved

2 2

Jardiance

Boehringer Ingelheim

Approved

2 3

Mazdutide

Eli Lilly

Phase 3

1 4

Angiotensin Receptor Blocker

NNational University of Ireland, Galway, Ireland

Phase 3

1 5

MTX-439

MMediar Therapeutics

Phase 1

1 6

AP303 150μg

AAlebund Pharmaceuticals

Phase 1

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Diabetic Kidney Disease

NCT07473323

Clinical

Trials by Indication[1]

Diabetic Kidney Disease1 trial

A Phase 1 Randomized, Double-blind, Dose-Escalating Study to Assess the Safety, Tolerability, and Pharmacokinetics of MTX-439 in Healthy Adults and Adults With Diabetic Kidney Disease

Recruiting·MMediar Therapeutics·Phase 1·NCT07473323·88 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MTX-439. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MTX-439 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MTX-439. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mediar Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: MMediar Therapeutics

MTX-439

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Diabetic Kidney Disease1 trial

References

Drug Info

Quick Facts

Related News